Publication

Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study

Tabernero, J
; 
Van, CE
; 
Bang, Y
; 
Fuchs, C
; 
Wyrwicz, L
; 
Lee, K
; 
Kudaba, I
; 
Garrido, M
; 
Chung, H
; 
Castro, SH
... show 9 more
Citations
Altmetric:
Abstract
Authors
Tabernero, J
Van, CE
Bang, Y
Fuchs, C
Wyrwicz, L
Lee, K
Kudaba, I
Garrido, M
Chung, H
Castro, SH
Mansoor, Was
Braghiroli, M
Goekkurt, E
Chao, J
Wainberg, Z
Kher, U
Shah, S
Kang, S
Shitara, K
Affiliation
Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain
Description
Date
2019
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Meetings and Proceedings
Citation
Tabernero J, Van Cutsem E, Bang Y, Fuchs C, Wyrwicz L, Lee K, et al. Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study. Ann Oncol. 2019;30 Suppl 4:iv152-iv3.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/622838
Embedded videos